Diepenbeek

Amakem Announces Further Proof-of-Concept Results for its ‘Localized Drug Action’ Platform

Amakem Raises 18m in a Series a Round to Advance its Ophthalmology Drug Development Programs

Discover the Easiest Approach to Web Based Audio and Video Calls: Intellivic Click-to-Call

DIEPENBEEK, Belgium, November 2, 2011 - Kinase inhibitor reduces inflammation in the lungs in COPD model with no cardiovascular side effects Amakem NV, a kinase platform company focusing on ophthalmology, today presented further data demonstrating the effectiveness of its 'Localized Drug Action' approach at the Discovery on Target conference in Boston, MA.

MORE..

DIEPENBEEK, Belgium, September 6, 2011 - 'Localized Drug Action' platform generates novel kinase inhibitors for eye conditions including glaucoma Amakem NV today announced it has raised €18m with a syndicate of leading life sciences investors to advance its ophthalmology drug development portfolio and progress its lead candidate, AMA0076 for glaucoma, to clinical proof of concept.

MORE..

Older News

DIEPENBEEK, Belgium - Intellivic Click-to-Call (www.intellivic.com/click2call) enables web users to make audio and/or video calls from within any website without installing any software.

MORE..